Lonza seen up on EBITDA beat, outlook hike for key CDMO business

Lonza AG

23/07/2025 07:33

** Shares of Swiss pharmaceutical supplier Lonza LONN.S are seen up 4.48% in pre-market indications after it beat consensus for H1 core EBITDA and raised outlook for its key business

** Analysts at J.P.Morgan say they expect the consensus beat and outlook hike for the contract drug manufacturing (CDMO) business to be well received

** "Expect the shares to outperform by 2-3% today," JPM says

** The results were good overall, analysts at Vontobel say, especially as Lonza's Vacaville site in the U.S., acquired in 2024, is "developing better than the management expected"

 (Reporting by Bernadette Hogg and Isabel Demetz)

 ((bernadette.hogg@thomsonreuters.com))